High prevalence of venous thrombotic events in Cushing's syndrome: data from ERCUSYN and details in relation to surgery.

Autor:	Isand K; Institute of Biomedicine and Translational Medicine, University of Tartu, Ülikooli 18, 50090, Tartu, Estonia., Feelders R; Department of Internal Medicine, Section of Endocrinology, ENETS Center of Excellence, Erasmus MC and Erasmus Cancer Institute, 3015 Rotterdam, The Netherlands., Brue T; Aix Marseille Univ, APHM, INSERM, MMG, Department of Endocrinology Hospital La Conception, MarMaRa Institute, 13305 Marseille, France., Toth M; Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary., Deutschbein T; Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, 97080 Würzburg, Germany., Reincke M; Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Ludwig-Maximilians-Universität München, 80336 Munich, Germany., Kršek M; Third Department of Internal Medicine, First Faculty of Medicine, Charles University, General University Hospital, 12808 Prague, Czech Republic., Santos A; IIB-Sant Pau and Department of Endocrinology, Hospital Sant Pau, Dept Medicine, UAB, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, 08025 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), Barcelona, Spain., Demtröder F; Zentrum für Endokrinologie, Diabetologie, Rheumatologie Dr. Demtröder & Kollegen, 44137 Dortmund, Germany., Chabre O; University Grenoble Alpes, UMR 1292 INSERM-CEA-UGA, Endocrinologie CHU Grenoble Alpes, F-38000 Grenoble, France., Strasburger CJ; Clinical Endocrinology, Charite-Universitätsmedizin, Campus Mitte, 10117 Berlin, Germany., Aulinas Maso A; IIB-Sant Pau and Department of Endocrinology, Hospital Sant Pau, Dept Medicine, UAB, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, 08025 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), Barcelona, Spain., Volke V; Institute of Biomedicine and Translational Medicine, University of Tartu, Ülikooli 18, 50090, Tartu, Estonia., Pereira AM; Department of Endocrinology & Metabolism, Amsterdam University Medical Center, and University of Amsterdam, 1081 Amsterdam, Netherlands., Lohmann R; Health Care Consulting GmbH, Lohmann & Birkner Health Care Consulting GmbH, 13407 Berlin, Germany., Gich Saladich I; Department of Clinical Epidemiology and Public Health, Hospital de la Santa Creu i Sant Pau (IIB Sant Pau), 08025 Barcelona, Spain., Webb SM; IIB-Sant Pau and Department of Endocrinology, Hospital Sant Pau, Dept Medicine, UAB, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, 08025 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), Barcelona, Spain., Wass J; Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals, OX37LE Oxford, United Kingdom., Valassi E; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), Barcelona, Spain.; Endocrinology and Nutrition Department, Germans Trias i Pujol Hospital and Research Institute, Badalona 08916, Spain.
Jazyk:	angličtina
Zdroj:	European journal of endocrinology [Eur J Endocrinol] 2024 Jan 03; Vol. 190 (1), pp. 75-85.
DOI:	10.1093/ejendo/lvad176
Abstrakt:	Objective: The aim of this study was to evaluate the prevalence of venous thromboembolism (VTE) in patients included in the European Registry on Cushing's syndrome (ERCUSYN), compare their clinical characteristics with those who did not develop VTE and identify risk factors for VTE. Design: A retrospective observational cohort study. Methods: Data extraction from the registry was taken on February, 7, 2022. At the time there were 2174 patients diagnosed with Cushing's syndrome (CS) and 95 VTEs were reported in the database. Results: Of 95 VTE events 70 (74%) were in pituitary-dependent CS patients, 12 (12.5%) in adrenal-dependant CS, 10 (10.5%) in ectopic CS, and 3 (3%) in CS due to other causes. Sex, 24-hour urinary free cortisol (UFC) value at diagnosis, as well as the number of operations remained statistically significant predictors of VTE. Of patients who were treated with at least one surgery, 12 (13%) VTE occurred before and 80 (87%) after the surgery. Nearly half of these VTEs occurred within six months since the operation (36; 45%). Over half of the centers that reported VTE did not routinely anticoagulate CS patients. Anticoagulation schemes varied widely. Conclusion: Patients with CS have an elevated risk of developing VTE for an extended period of time. From ERCUSYN cohort patients have higher risk for VTE if they need multiple surgeries to treat CS, are males and have high UFC values at the diagnosis of CS. Since there is no agreement on thromboprohpylaxis, a protocol for VTE prevention that is widely adopted appears to be necessary for patients with CS. Competing Interests: Conflict of interest: None declared. (© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu